Over 50 companies are advancing 55+ therapies for Follicular Lymphoma, highlighting a robust clinical trial pipeline.
Read more
PTC Therapeutics partners with Novartis for Huntington's Disease therapy, securing $1 billion upfront and potential $1.9 billion in milestones.
Read more
Oligonucleotide Synthesis Market to grow by USD 3.37 billion by 2028, driven by RNA-based therapeutics and AI integration.
Read more
Allink Biotherapeutics raises $42M to advance bispecific antibody and ADC pipeline for oncology and immunology.
Read more
Senti Bio's SENTI-202 shows promising results in Phase 1 trial for relapsed/refractory acute myeloid leukemia.
Read more
Idorsia plans layoffs and a potential $35M licensing deal for hypertension drug Tryvio to ensure financial sustainability.
Read more
AAVantgarde Bio's AAVB-081 receives FDA Orphan Drug Designation for Usher Syndrome Type 1B Retinitis Pigmentosa.
Read more
Novartis invests $1B in PTC's Huntington Disease therapy, aiming for first disease-modifying treatment.
Read more
OraSure receives $7.5M federal funding for Marburg Virus Disease rapid antigen test development.
Read more
FDA accepts NDA resubmission for Satsuma's STS101 for acute Migraine treatment, PDUFA date set for April 2025.
Read more
Olema and Novartis collaborate on Phase 3 trial for ER+/HER2- metastatic breast cancer, securing $250M in funding.
Read more
Aidoc submits CARE1â„¢ AI model for FDA review, aiming to revolutionize CT imaging with enhanced diagnostic accuracy and efficiency.
Read more
Susanna High appointed CEO of Paragon Therapeutics, with Lee Patterson leading Metrion Biosciences.
Read more
FDA approves Mentor's MemoryGel Enhance Breast Implants for larger breast reconstruction sizes, expanding options for post-mastectomy patients.
Read more
Astorg acquires Hamilton Thorne and Cook Medical RH to form a global ART MedTech leader.
Read more
XOMA acquires Pulmokine for $20M, adding Phase 3 seralutinib for Pulmonary Arterial Hypertension to its royalty portfolio.
Read more
AI-driven growth to boost Medical Aesthetics Market by USD 18.8 billion from 2024-2028, despite high treatment costs.
Read more
JELMYTO shows a median response duration of 47.8 months in low-grade Upper Tract Urothelial Cancer patients.
Read more
FDA approves Biocon's YESINTEK, a biosimilar for Crohn's Disease, Ulcerative Colitis, Plaque Psoriasis, and Psoriatic Arthritis.
Read more
MaaT Pharma's MaaT033 shows safety and tolerability in Phase 1b trial for Amyotrophic Lateral Sclerosis.
Read more
Nemolizumab shows significant improvement in Prurigo Nodularis symptoms in Phase III trial, leading to FDA approval.
Read more
BriaCell's Phase 3 study in Metastatic Breast Cancer continues with DSMB's safety approval.
Read more
Oncolytics Biotech advances breast and pancreatic cancer trials, aiming for FDA accelerated approval.
Read more
FDA accepts Cytokinetics' NDA for aficamten to treat Obstructive Hypertrophic Cardiomyopathy, with a PDUFA date set for September 2025.
Read more
Sarepta partners with Arrowhead for siRNA programs targeting rare genetic diseases, enhancing its pipeline in muscle, CNS, and lung disorders.
Read more
